Replimune’s mission is to revolutionize cancer treatment with therapies designed to activate a powerful and durable full-body anti-tumor response, boldly transforming cancer care because patient’s lives depend on it. We imagine a world where cancer is a curable disease.
At Replimune, we live by our values:
United: We Collaborate for a Common Goal.
Audacious: We Are Bold and Innovative.
Dedicated: We Give Our Full Commitment.
Candid: We Are Honest With Each Other.
People are at the center of everything we do, and when it comes to our employees, we make it personal. With a deep sense of purpose, an innovative and collaborative culture, a competitive and forward-looking total rewards program, everyone at Replimune has a unique opportunity to contribute to the meaningful work we do which could impact the lives of patients.
Join us, as we reshape the future.
Job Summary:
The Manager, Quality Assurance Operations (QA Ops) reports to the Associate Director QA Ops and is responsible for on-going Quality oversight to ensure products are manufactured, tested, stored, and distributed according to current good manufacturing practices (cGMP), good documentation practices (GDP) and other applicable regulations. The Manager QA Ops will work with cross functional teams to maintain and present the internal quality systems associated with GxP activities to ensure the successful and timely release of drug substance, drug product and clinical trial material by providing quality oversight of the overall release, packaging and labeling processes. The Manager QA Ops will provide leadership, direction and delegation of work to the QA Ops staff.
This position is based in our Framingham location and typically has a 5-day on-site expectation.
Key responsibilities:
Other responsibilities
Education:
Required Experience:
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of a novel portfolio of oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to ignite a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.
We are an Equal Opportunity Employer.
#LI-onsite
Software Powered by iCIMS
www.icims.com